Management of Glucocorticoid-Induced Osteoporosis

Introduction to Guideline Recommendations

• The American College of Rheumatology recommends immediate pharmacologic treatment with an oral bisphosphonate (alendronate or risedronate) as first-line therapy for high fracture risk GIOP patients aged ≥40 years, combined with calcium (1,000-1,200 mg daily) and vitamin D (800-1,000 IU daily) supplementation 1, 2

Risk Stratification

• Patients with a T-score of -2.3 meet the definition of high fracture risk and require FRAX calculation with glucocorticoid dose adjustment to fully stratify risk 1, 2
• If the prednisone dose is >7.5 mg/day, multiply the 10-year risk of major osteoporotic fracture by 1.15 and hip fracture risk by 1.2 1, 2

Initial Assessment Requirements

• A detailed glucocorticoid history, comprehensive fracture risk assessment, and evaluation for secondary causes of osteoporosis are essential before initiating treatment 1, 2
• Lifestyle factors such as alcohol use, smoking, low body weight, and significant weight loss should also be assessed 1, 2

First-Line Pharmacologic Treatment

• Oral bisphosphonates are strongly recommended as first-line therapy for high fracture risk GIOP patients aged ≥40 years 1, 2
• Risedronate is an equally effective alternative to alendronate 1, 2

Essential Baseline Supplementation

• All patients must receive calcium and vitamin D optimization regardless of pharmacologic therapy chosen, with calcium 1,000-1,200 mg daily and vitamin D 800-1,000 IU daily 1, 2, 4

Monitoring and Follow-Up

• BMD with VFA or spinal x-rays should be repeated every 1-2 years during osteoporosis therapy, with more frequent monitoring warranted if very high-dose glucocorticoids are used or if there is a history of fracture occurring after ≥18 months of treatment 1, 2, 5, 6

Critical Sequential Therapy Considerations

• If switching to denosumab, romosozumab, or PTH/PTHrP analogs, sequential therapy is mandatory to prevent rebound bone loss and vertebral fractures 7, 8
• Never discontinue denosumab without transitioning to bisphosphonate 6-9 months after the last dose 7

Special Considerations for Very High-Risk Patients

• Anabolic agents (PTH/PTHrP) are conditionally recommended over antiresorptive agents as initial therapy for very high-risk patients 1, 2, 7
• This represents a shift toward prioritizing bone formation in the highest-risk patients 1, 2